Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says

MT Newswires Live2025-12-23

Zenas BioPharma (ZBIO) shares are seen as attractive ahead of the Phase 3 topline results for obexelimab, expected in the week of Jan. 5 for the treatment of IgG4-RD autoimmune disease, Wedbush said Monday in a report.

The early January timing is most likely, offering clarity after the holiday period and ahead of the JP Morgan Healthcare Conference on Jan. 12-15, Wedbush said.

Zenas shares rose 8.3% in recent Monday trading. Wedbush reiterated its outperform rating on the stock with a $45 price target.

Obexelimab, if approved, is expected to reach about 35% market share as a second entrant in IgG4-related disease, the report said.

IgG4-RD is a chronic autoimmune condition that can cause inflammation and organ damage across multiple systems. Obexelimab "has a less harsh mechanism of action," and "key differentiators include safety, convenience, and ability to pause treatment," Wedbush said.

Wedbush projects a US launch in mid-2027 and a European launch in early 2028, with estimated global sales of $8.5 million in 2027, $100 million in 2028, $270 million in 2029, and $515 million in 2030.

Price: 39.14, Change: +2.99, Percent Change: +8.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593543113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593543113","market":"nz","top_or_hot":-1,"title":"Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Zenas BioPharma (ZBIO) shares are seen as attractive ahead of the Phase 3 topline results for obexelimab, expected in the week of Jan. 5 for the treatment of IgG4-RD autoimmune disease, Wedbush said Monday in a report.</p><p>The early January timing is most likely, offering clarity after the holiday period and ahead of the JP Morgan Healthcare Conference on Jan. 12-15, Wedbush said.</p><p>Zenas shares rose 8.3% in recent Monday trading. Wedbush reiterated its outperform rating on the stock with a $45 price target.</p><p>Obexelimab, if approved, is expected to reach about 35% market share as a second entrant in IgG4-related disease, the report said.</p><p>IgG4-RD is a chronic autoimmune condition that can cause inflammation and organ damage across multiple systems. Obexelimab \"has a less harsh mechanism of action,\" and \"key differentiators include safety, convenience, and ability to pause treatment,\" Wedbush said.</p><p>Wedbush projects a US launch in mid-2027 and a European launch in early 2028, with estimated global sales of $8.5 million in 2027, $100 million in 2028, $270 million in 2029, and $515 million in 2030.</p><p>Price: 39.14, Change: +2.99, Percent Change: +8.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 00:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zenas BioPharma (ZBIO) shares are seen as attractive ahead of the Phase 3 topline results for obexelimab, expected in the week of Jan. 5 for the treatment of IgG4-RD autoimmune disease, Wedbush said Monday in a report.</p><p>The early January timing is most likely, offering clarity after the holiday period and ahead of the JP Morgan Healthcare Conference on Jan. 12-15, Wedbush said.</p><p>Zenas shares rose 8.3% in recent Monday trading. Wedbush reiterated its outperform rating on the stock with a $45 price target.</p><p>Obexelimab, if approved, is expected to reach about 35% market share as a second entrant in IgG4-related disease, the report said.</p><p>IgG4-RD is a chronic autoimmune condition that can cause inflammation and organ damage across multiple systems. Obexelimab \"has a less harsh mechanism of action,\" and \"key differentiators include safety, convenience, and ability to pause treatment,\" Wedbush said.</p><p>Wedbush projects a US launch in mid-2027 and a European launch in early 2028, with estimated global sales of $8.5 million in 2027, $100 million in 2028, $270 million in 2029, and $515 million in 2030.</p><p>Price: 39.14, Change: +2.99, Percent Change: +8.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593543113","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593543113","pubTimestamp":1766422770,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zenas BioPharma  shares are seen as attractive ahead of the Phase 3 topline results for obexelimab, expected in the week of Jan. 5 for the treatment of IgG4-RD autoimmune disease, Wedbush said Monday in a report.The early January timing is most likely, offering clarity after the holiday period and ahead of the JP Morgan Healthcare Conference on Jan. 12-15, Wedbush said.Zenas shares rose 8.3% in recent Monday trading. Wedbush reiterated its outperform rating on the stock with a $45 price target.Obexelimab, if approved, is expected to reach about 35% market share as a second entrant in IgG4-related disease, the report said.IgG4-RD is a chronic autoimmune condition that can cause inflammation and organ damage across multiple systems. Obexelimab \"has a less harsh mechanism of action,\" and \"key differentiators include safety, convenience, and ability to pause treatment,\" Wedbush said.Wedbush projects a US launch in mid-2027 and a European launch in early 2028, with estimated global sales of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc.","BK4139":"生物科技"},"translate_title":"Wedbush表示，Zenas BioPharma在IgG4-RD 3期更新之前具有吸引力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":1},"content_text":"Zenas BioPharma (ZBIO) shares are seen as attractive ahead of the Phase 3 topline results for obexelimab, expected in the week of Jan. 5 for the treatment of IgG4-RD autoimmune disease, Wedbush said Monday in a report.The early January timing is most likely, offering clarity after the holiday period and ahead of the JP Morgan Healthcare Conference on Jan. 12-15, Wedbush said.Zenas shares rose 8.3% in recent Monday trading. Wedbush reiterated its outperform rating on the stock with a $45 price target.Obexelimab, if approved, is expected to reach about 35% market share as a second entrant in IgG4-related disease, the report said.IgG4-RD is a chronic autoimmune condition that can cause inflammation and organ damage across multiple systems. Obexelimab \"has a less harsh mechanism of action,\" and \"key differentiators include safety, convenience, and ability to pause treatment,\" Wedbush said.Wedbush projects a US launch in mid-2027 and a European launch in early 2028, with estimated global sales of $8.5 million in 2027, $100 million in 2028, $270 million in 2029, and $515 million in 2030.Price: 39.14, Change: +2.99, Percent Change: +8.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593543113","isCrawlerRequest":true}